CRCs in the News

  • Cancer Therapeutics CRC signs huge agreement with Pfizer
    Melbourne-headquartered Cancer Therapeutics CRC (CTx) last week announced a two-year research collaboration and a license agreement with Pfizer Inc.. Under the terms of the agreement, Pfizer will gain the rights to two novel pre-clinical cancer programs and CTx will receive US$14.2 million (AUD$20M) upfront payment, up to a potential US$460 million (AUD$648M) in development and sales milestones, as well as royalties on product sales if the program reaches commercialization.

Read more CRC news articles